As PD-(L)1 disruptors suffer setbacks, Checkpoint touts another win
FDA officials put a dent in some biopharmas’ quest to disrupt PD-(L)1 pricing, as many had attempted to shuttle through drugs using data from single-country trials. But Checkpoint Therapeutics is continuing to build out a case for its own checkpoint inhibitor, and appears to be suffering no such setbacks.
The Massachusetts biotech said Thursday that an interim readout for its anti-PD-L1 antibody cosibelimab induced responses in 17 of 31 patients with locally advanced cutaneous squamous cell carcinoma, good for a 54.8% ORR. Checkpoint hopes to add this indication as a second label to its FDA application when it submits later this year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.